HC Wainwright Maintains Buy on Genmab with $50 Price Target
HC Wainwright & Co. has reiterated its Buy rating on Genmab's stock, setting a price target of $50.00. This target suggests a significant potential downside from the recent closing price.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.